Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for the Long Term. Eli Lilly and Company ...

Eli Lilly's popular drug Mounjaro will be added to China's state-run health insurance scheme from January 1 for patients with ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker. Lilly said Thursday that its ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Eli Lillys diabetes drug Mounjaro is set to join Chinas state-run health insurance reimbursement list on January 1, according ...